IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY EGFR ANTIBODY
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and an EGFR antibody such as cetuximab. The anti-cancer effect of cetuximab is enhanced in the presence of SIRPαFc. Specific combinations include SIRPαFc forms that comprise an Fc that is either IgGl or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.
1 . A method for treating a subject presenting with disease cells that are CD47+ and EGFR+, comprising administering to the subject a combination of a SIRPαFc protein and an epidermal growth factor receptor (EGFR) antibody.
2 . The method according to claim 1 , wherein the EGFR antibody is cetuximab.
3 . The method according to claim 1 , wherein the EGFR antibody is Erbitux®.
4 . The method according to claim 1 , wherein the EGFR antibody is panitumumab.
5 . The method according to claim 1 , wherein the EGFR antibody is Vectibix®.
6 . The method according to claim 1 , wherein the SIRPαFc drug comprises SEQ ID No. 6.
7 . The method according to claim 1 , wherein the SIRPαFc drug comprises SEQ ID No.7.
8 . The method according to claim 1 , wherein the CD47+ disease cells are cancer cells.
9 . The method according to claim 8 , wherein the cancer cells are blood cancer cells or solid tumour cells, optionally head and neck cancer cells or colorectal cancer cells.
10 . The method according to claim 9 , wherein the cancer cells are blood cancer cells.
11 . The method according to claim 10 , wherein the blood cancer cell is a leukemia, a lymphoma or a myeloma.
12 . The method according to claim 11 , wherein the leukemia is selected from acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML); chronic lymphocytic leukemia (CLL); and chronic myelogenous leukemia (CML).
13 . The method according to claim 11 , wherein the cancer is a lymphoma selected from a Hodgkin's lymphoma, both indolent and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma (small cell and large cell).
14 . The method according to claim 11 , wherein the cancer is a myeloma selected from multiple myeloma (MM), giant cell myeloma, heavy-chain myeloma, light chain or Bence-Jones myeloma, myeloproliferative disorder/neoplasm (MPDS); and myelodysplastic syndrome.
15 . The method according to claim 1 , wherein the EGFR antibody is administered to a subject that has already received the SIRPαFc drug.
16 . (canceled)
17 . A pharmaceutical combination comprising an effective amount of a SIRPαFc drug, and an effective amount of an EGFR antibody.
18 . The combination according to claim 17 , wherein the EGFR antibody is cetuximab.
19 . The combination according to claim 17 , wherein the SIRPαFc drug comprises SEQ ID No. 6.
20 . The combination according to claim 17 , wherein the SIRPαFc drug comprises SEQ ID No. 7.
21 . A kit comprising a combination of claim 17 , and written instructions for the use thereof for the treatment of a subject presenting with CD47+ disease cells.
22 . (canceled)